Recent studies using gene-targeted and hormone-treated mice have implicated bone-lining osteoblasts as important regulators of hematopoietic stem cell (HSC) self-renewal and differentiation; however, as much of the evidence supporting this notion derives from indirect in vivo experiments, which are unavoidably complicated by the presence of other cell types within the complex bone marrow milieu, the sufficiency of osteoblasts in modulating HSC activity has remained controversial 1 . To address this issue, we prospectively isolated mouse osteoblasts, using a novel, flow cytometry-based approach, and directly tested their activity as HSC niche cells and their role in cyclophosphamide/G-CSF (Cy/G) induced HSC proliferation and mobilization. We found that osteoblasts expand rapidly following Cy/G treatment and exhibit significant phenotypic and functional changes that directly influence their ability to support HSC proliferation and maintenance of reconstituting potential. Furthermore, these effects of mobilization on osteoblast number and function depend on the function of ATM, the product of the ataxia telangiectasia mutated (Atm) gene, demonstrating a new role for this kinase in supporting stem cell niche activity. Taken together, these studies demonstrate that signals from osteoblasts can directly initiate and modulate HSC proliferation in the context of mobilization.
INTRODUCTION
Mature blood cells have a finite lifespan which necessitates their constant replenishment from self-renewing, multipotent hematopoietic stem cells (HSCs) 2 . HSC maintenance and expansion are thought to be regulated by interactions with BM stromal elements, including osteoblasts [3] [4] [5] , and vascular endothelial cells 1 , both of which have been proposed to form a supportive HSC "niche" 3, [6] [7] [8] . Osteoblasts, in particular, have been implicated in controlling HSC numbers, and studies in gene-targeted 3 and hormone-treated 6,9 mice show a strong correlation between experimentally-induced expansion of osteoblasts and increased HSC frequency.
Significantly, most studies of osteoblast function as it relates to HSC have relied on complex in vivo models [10] [11] [12] [13] , or on in vitro systems in which osteoblasts are derived ex vivo by extended culture of calvarial precursor cells 10 . While suggestive, these in vivo analyses are complicated by the unavoidable presence of other, non-osteoblastic cell types, while in vitro studies of culturederived osteoblasts are challenged by the possibility that extended culture may induce changes in osteoblast behavior and/or may fail to properly recapitulate the in vivo conditions under which osteoblasts normally would be formed or regulated. For these reasons, it has been difficult to establish the particular aspects of HSC function that depend on the osteoblastic niche, and this has generated significant controversy regarding the specific role of osteoblasts in HSC regulation 1, 14, 15 .
To overcome these earlier complications, in this study, we develop and utilize a novel strategy to prospectively isolate mouse osteoblasts and test the function of these cells as regulatory niche cells for HSC. Through a battery of phenotypic and functional assays, we demonstrate that osteoblasts can be prospectively identified and purified by fluorescence activated cell sorting (FACS) from marrow-depleted, enzymatically-treated mouse bones. Using this direct approach, we further demonstrate that in response to pharmacological mobilization, increases in the in vivo frequency and numbers of prospectively identified osteoblasts immediately precede parallel increases in the frequency and number of HSC, suggesting that increased niche availability may enable stem cell expansion in response to mobilization. Finally, we show that freshly-isolated osteoblasts from either untreated or mobilized mice can communicate directly with HSC and are themselves sufficient to induce physiologically relevant changes in HSC function, and that this function depends, at least in part, on the protein kinase ataxia telangiectasia mutated (ATM). In particular, short-term in vitro exposure assays indicate that normal osteoblasts maintain HSC function in part by holding them in a quiescent state through direct cell-cell contact, while mobilizing agents induce changes in osteoblastic niche cells that cause them to elaborate soluble factors that instead promote HSC proliferation while maintaining their functional reconstituting potential. Interestingly, these mobilization-induced changes in both osteoblast number and support of HSC function are diminished in the absence of ATM, a kinase previously implicated in regulating oxidative stress 16 17,18 , inflammation 19, 20 , bone remodeling 21 , and stem cell self-renewal [22] [23] [24] .
Together, these data underscore the importance of the HSC microenvironment in determining HSC activity and highlight the dynamic nature of the HSC niche. Moreover, by using purified cell populations, this study provides the first clear evidence that direct interactions between hematopoietic precursors and osteolineage niche cells, without any other environmental inputs, are sufficient to specifically modulate HSC number and function. The capacity of purified osteoblasts to act as autonomous regulators of HSC activity in vitro further establishes a new and powerful system that for the first time permits direct interrogation of the interactions of stem cells with their niche and reveals novel and fundamental aspects of stem cell regulation that supplemented with 2% donor bovine serum (DBS). For Annexin V staining, cells were washed in Annexin V staining buffer (0.01 M HEPES, pH 7.4; .14 M NaCl; 2.5 mM CaCl) after first staining for cell surface markers, and then incubated with Annexin V specific antibody (5μl/100μl) for 15 mins. Propidium Iodide (PI) was used as a marker for cell viability and added to samples just prior to sample acquisition. Flow cytometric experiments were performed using an LSRII, FACS-Aria (BD Biosciences) or Moflo (Dako). Data were analyzed with FlowJo software (Treestar) and represented as histograms, contour, or dot plots of fluorescence intensity.
BM cell and Osteoblast Isolation
Total BM cells were isolated from mouse femurs and tibias by flushing with HBSS + 2% FBS.
RBCs and debris were removed by ACK lysis and filtering through nylon mesh. Osteoblasts were isolated from marrow-depleted bones by mechanical disruption (crushing with mortar and pestle) and enzymatic digestion in 0.1% collagenase + 0.05% dispase for 1 hour. Boneassociated cells liberated by enzymatic treatment were collected by centrifugation (5 min, 1200 rpm). DTT and 1000 units RNasin Ribonuclease Inhibitor/ml of buffer). This was followed immediately by centrifugation, and RT-PCR analysis was performed according to standard protocols as described above. The contents of each well were reverse transcribed in the presence of oligo-dT and random hexamer and the final cDNA product in each well was divided equally for amplification with gene specific primers.
Quantitative RT-PCR

ELF-97-Alkaline Phosphatase assays
ALP activity was measured using the ELF-97 Endogenous Phosphatase Detection Kit (Molecular Probes) per the manufacturer's instructions with a modification for flow cytometric analysis as described previously 61 . Isolated OSBs were washed twice in 0.15M normal saline solution without phosphate buffers. The ELF-97 phosphate substrate was added to cells preincubated in ELF-97 developing buffer (15min) in a final volume of 100 μl (1:20 in provided buffer). Cells were incubated in the dark at room temperature for 1 to 30 min, followed by the addition of the phosphatase inhibitor levamisole (10mM) to all tubes to stop the reaction. The cells were then analyzed by flow cytometry (Moflo, Dako) within 1 hr.
Bone Nodule assays
OPN + cells were plated at a density of 10 cells per well in a 96 well plate containing α-MEM supplemented with 15% FBS, 100U/mL penicillin and 1mg/ml streptomycin. On day 15 of culture, ascorbic acid (20mg/ml) and β-glyceraldehyde (50μM) were added to each well. 7 days (d22 after culture start) and 15 days (d30 after culture start) after addition of ascorbic acid and β-glyceraldehyde, cultures were screened for bone nodule formation as well as ALP gene expression and activity. To detect mineralization of bone nodules, cell cultures were stained with 1% silver nitrate (von Kossa method). Briefly, the cell cultures were washed twice with PBS, fixed in phosphate buffered formalin for 10 min, washed once with water, and serially dehydrated in 70%, 95%, and 100% EtOH two times each and air dried. The plates were then rehydrated from 100% to 95% to 80% EtOH to H2O. The water was removed, a 1% silver nitrate solution was added, and the plate was exposed to light for 20 minutes after which the plate was rinsed with water. Sodium thiosulfate (5%) was added for 3 minutes and rinsed with water; mineral is stained dark red to black.
Cy/G treatment, in vivo BrdU administration and BrdU staining
Mobilization of HSC by combined administration of cyclophosphamide (Cy) + G-CSF was performed as described previously 43 analysis and compared to control populations of HPCs that were either left unlabeled (negative control), freshly labeled with CFSE or had been CFSE labeled and stored at 4ºC for the duration of the experiment (positive control for undivided fraction). For transwell assays, experiments were performed as described above except osteoblasts were cultured in the top well of a transwell chamber and physically separated by a 0.4 micron pore from HPCs present in the bottom well.
Hematopoietic progenitor cell isolation and BM Transplantation
HPCs for co-culture experiments were isolated from WT (for CFSE studies, 
Statistical Analysis
Results are expressed as mean +/-standard deviation (SD). Data were analyzed using the unpaired two-tailed Student's t-test or a one-way ANOVA as appropriate for the data set.
P≤0.05 was considered significant.
RESULTS
Osteoblasts can be isolated by direct cell sorting
To facilitate direct studies of osteoblast function in the regulation of homeostatic and regenerative HSC function, we established parameters for flow cytometry-based identification and isolation of bone-associated osteoblasts from enzymatically digested bone. Long bones (femurs and tibias) harvested from wild type C57BL/Ka mice were first depleted of marrow by flushing with a syringe, and then gently crushed with a mortar and pestle to generate ~1mm Fig. 1 ). 
Osteoblasts expand during Cy/G-induced HSC mobilization
HSCs normally are highly quiescent 39, 40 and reside primarily in the BM, although they also can be found at low frequency in the circulatory system of normal animals 41, 42 . HSC proliferation and migration from the BM to the bloodstream can be dramatically increased by the use of stem cell "mobilizing agents" 43, 44 . One well-studied regimen for HSC mobilization involves sequential daily treatment with the cytotoxin, cyclophosphamide (Cy) and the cytokine, granulocyte-colony stimulating factor (G-CSF) [42] [43] [44] [45] (see Fig. 3 ). Following administration of Cy plus 2 daily doses of G-CSF, referred to as day+2 (D2) of the Cy/G regimen (Fig. 3A) , the BM HSC population exhibits robust proliferation and expansion to numbers 10-12 times those seen in untreated mice 40, 43 . After D2, HSCs begin to exit the BM, and are detected at increased frequency in the blood and peripheral organs by days +3 (D3) and +4 (D4) 43, 44 . By D4 of Cy/G treatment, the rate of HSC proliferation in the BM returns approximately to normal, and the population size shrinks to steady state levels 40, 43 .
Given that previous studies in which osteoblast numbers have been experimentally manipulated have suggested that the number and/or availability of these cells may directly regulate the number of HSC 3-6 , we wondered whether the dramatic expansion of HSC that occurs in response to Cy/G treatment might be accompanied by a concomitant expansion of osteoblastic niche cells. To test this possibility, we used flow cytometry to directly enumerate osteoblasts harvested fresh from the long bones of untreated or Cy/G mobilized mice (Fig. 3) .
Upon Cy/G treatment, both the frequency ( . 3B ); however, osteoblast frequencies and numbers returned to normal (i.e. equivalent to the frequency and number of OPN + cells seen in untreated animals by D4 (Fig. 3B, C) ). Precisely how homeostasis is restored to the osteoblast compartment by D4 of Cy/G-treatment remains unclear, and is a topic of ongoing investigation.
Interestingly, in contrast to mice treated with Cy/G, in animals receiving G-CSF alone (for 2 days), we observed no detectable increase in the frequency of OPN + cells (G2, 2 ± 1% OPN + ), compared to mice left untreated (UNT, 2.5 ± 2% OPN + ; Supplementary Fig. 3 ). The observation that osteoblasts are not induced by treatment with G-CSF alone is consistent with previous studies 46, 47 , and correlates with earlier observations that treatment of mice with G-CSF results in only mild expansion of BM HSC 44, 48 , as opposed to the dramatic (10-12 fold) expansion of BM HSC in mice treated with the combination of Cy+G-CSF 42, 43 .
To more directly assess changes in the proliferative activity of osteoblasts in Cy/Gtreated mice, we also measured incorporation of bromodeoxyuridine (BrdU) by these cells during mobilization treatment. Mice were treated as before with Cy/G, and additionally received daily injections of BrdU (1mg/ml, i.p.) to label dividing cells. BrdU labeling was initiated at the same time for all experimental groups (UNT, D0, D2, D4) and this time point coincided with Cy administration in the first experimental group to begin treatment (12 hours after Cy administration in the D4 experimental group). Labeling was continued for all animals by i.p.
injection every 12 hours until the animals were sacrificed (Fig. 3A, green arrows) . Thus, all animals in this experiment received comparable amounts of BrdU over precisely the same period of time (4.5 days).
As shown in Figure 3D , in untreated mice few OPN + cells divided during the 4.5 days of BrdU labeling (17 ± 5% BrdU + ). However, Cy/G treatment dramatically increased the rate of osteoblast proliferation over this time period, with 32 ± 4 % of isolatable OPN + cells labeled with BrdU in D0 mice, 50 ± 8 % in D2 mice, and 75 ± 6 % BrdU + in D4 mice. These data indicate that Cy/G treatment activates proliferation of osteolineage cells, which leads to substantial increases in osteoblast frequency and absolute numbers. Interestingly, osteoblast expansion appears to precede HSC expansion in the Cy/G model (Fig. 3) , as HSC are maximally expanded at D2 43, 44 . These data support the notion that the expansion of "niche" cells initiates or is required for subsequent expansion of functional HSC.
To further understand the effects of HSC mobilizing treatments on osteoblasts, we next assessed ALP enzymatic activity in these cells during the Cy/G treatment protocol. While bonespecific ALP activity in OPN + cells isolated from G-CSF only (G2) treated mice was increased compared to osteoblasts harvested from untreated (UNT) control mice, osteoblasts isolated from D2 Cy/G treated mice showed lower ALP activity (Supplementary Fig. 3B ). Importantly, ALP activity in all OPN + cell populations was always substantially higher than that of a predominantly hematopoietic negative control population (Supplementary Fig. 3B ). Given that ALP activity typically increases as osteolineage cells progress from proliferative preosteoblasts to mature, matrix secreting osteoblasts 12, 30, 31, 38 , these differences in ALP activity likely reflect differences in the predominant state of osteoblast differentiation in untreated, Cy/G-treated, and G only-treated mice. Increased ALP activity in G-only treated mice is indicative of a shift towards a more differentiated osteoblast population in these animals. In contrast, reduced ALP activity in Cy/G treated mice indicates the presence of a less differentiated population, and is consistent with their increased proliferative activity (Fig. 3D) , which is typical of less mature osteolineage cells. Thus, in addition to proliferative expansion, osteolineage cells exhibit phenotypic changes in response to Cy/G treatment that could influence the interactions of these niche cells with HSC in mobilized mice. Figure 4A ). The average input HSC frequency in these cultures was 4 ± 1.8% (Fig. 4B) . After 12 hrs., the total frequency of primitive c-Kit To further assess the effects of osteoblasts on HSC proliferation, we also used carboxyfluoroscein succinimidyl ester (CFSE) dilution assays to examine HSC division rates after 36 hr. exposure to normal or D2 mobilized OPN + cells. These assays revealed a striking difference in the rate of CFSE loss among KTLS HSC exposed to D2 osteoblasts, as compared to HSC in the presence of UNT osteoblasts or HSC cultured alone. Both the fraction of dividing HSC and the average number of HSC divisions were substantially higher among HSC exposed to D2 osteoblasts (Fig. 4C, D) . As noted above, this increased HSC proliferation in the presence of D2 osteoblasts was accompanied by a significant increase in relative frequency and overall numbers of HSC in D2 OSB:HSC co-cultures, as compared to either UNT OSB:HPC or HPC alone cultures (Fig. 4B, Supplementary Fig. 4A ). Interestingly, transwell assays, in which cellcell contact between the input osteoblast and hematopoietic populations could be prevented Next, to determine whether increases in HSC frequency and number in the presence of D2 osteoblasts might be facilitated by enhanced HSC survival in addition to increased proliferation (Fig. 4C, D) (Fig. 4E) .
Mobilizing agents induce changes in osteoblastic niche cells that influence HSC proliferation
These data indicate that osteoblasts provide an anti-apoptotic signal to HSC ex vivo and that this effect is unaltered by Cy/G-treatment. Moreover, these data argue that the increases in KTLS HSC frequency (Fig 4B) and number ( Fig. 4F) observed in the presence of D2 osteoblasts result from increased HSC proliferation (Fig. 4C, D) , rather than enhanced survival (Fig. 4E) .
Together with the transwell experiments described above, these data suggest a model wherein, in the steady-state, osteoblasts negatively regulate stem cell expansion through direct contact with HSC, while "mobilized" osteoblasts (D2) overcome this inhibition of HSC proliferation by elaboration and/or inhibition of a soluble factor(s) that acts on hematopoietic precursors.
Mobilization induces changes in osteoblastic niche cells that influence HSC function
Osteoblasts have been implicated as important regulators of HSC function 3, 7 . A hallmark function of HSC is their capacity to engraft and reconstitute hematopoiesis in lethally irradiated recipients. To test whether HSC proliferation in the presence of osteoblasts may better support HSC reconstituting activity than HSC proliferation in the absence of osteoblasts (i.e., in HPC only cultures), we compared the in vivo hematopoietic engraftment potential of untreated, wild-type HSC previously exposed for 12 hours only to either UNT or D2 osteoblasts, or to control conditions lacking osteoblasts (Fig. 5A) . HSCs derived from HPC:UNT cultures exhibited a less robust engraftment potential than those from HPC:D2 cultures, the engraftment potential in this population was still enhanced when compared to hematopoietic reconstitution in mice transplanted with cells from HPC only cultures (Fig. 5B, light gray bar) . Thus, these transplantation assays demonstrate a graded ability of these different conditions to maintain or expand HSC activity, with the level of HSC activity highest among cells exposed to D2 OPN + cells, lower among cells exposed to UNT osteoblasts, and
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For personal use only. on June 9, 2017. by guest www.bloodjournal.org From lowest among cells cultured in the absence of osteoblasts. Because engraftment potential is a direct measure of HSC activity, the increased hematopoietic reconstitution in D2 transplanted mice (Fig. 5B) , combined with the increased frequency and proliferation of KTLS HSC (Fig. 4B,   C, D) , suggest that D2 osteoblasts directly promote HSC proliferation while maintaining HSC self-renewal and functional activity.
Ataxia telangiectasia mutated (ATM) mediates the mobilization-induced changes in osteoblastic niche cells that influence HSC proliferation and function
The preceding data clearly indicate that osteolineage cells, prospectively isolated fresh from the bone, can directly communicate with HSC and modulate their function in response to physiological stimuli, such as mobilization. To better understand the molecular mechanisms involved in mobilization-induced changes in the osteoblastic niche, we sought to determine which signaling pathways might be essential to mediate Cy/G-induced increases in osteoblast proliferation and HSC support function. In surveying existing literature, we became particularly interested in the potential role of the 'ataxia telangiectasia mutated' (Atm) gene. Atm encodes a protein Ser/Thr kinase that helps to maintain genomic stability by activating proteins involved in the G1/S and G2/M cell-cycle checkpoints in response to DNA damage, telomeric instability or oxidative stress 51, 52 . Studies of Atm -/-(ATM KO) mice have implicated this kinase both in the intrinsic maintenance of HSC self-renewal and in the maintenance of appropriate bone mass in vivo 21, 22, 24 ; however, whether these represent completely independent or linked biological roles of ATM has not been clear. Figure 6F , P=0.0369).
To confirm that the decreased HSC frequency among HPCs exposed to ATM KO osteoblasts represents a decrease in the maintenance of functional HSC, we also compared the in vivo hematopoietic engraftment potential of untreated, WT HPC exposed for 12 hours to equal numbers of either ATM KO D2 osteoblasts (HPC:ATM KO D2) or WT D2 osteoblasts (HPC:WT D2), or to control conditions (HPC:WT UNT; HPC:ATM KO UNT; HPC only). In addition, in these studies, we also compared HSC engraftment after in vitro exposure to sorted OPN + cells to engraftment from freshly isolated, uncultured HPC (HPC UNC).
As in previous experiments, WT HPCs exposed to WT D2 osteoblasts showed significantly greater hematopoietic engraftment potential than HPCs exposed to WT UNT osteoblasts. In fact, reconstitution by HPCs exposed to WT D2 osteoblasts exceeded that of an equivalent number of freshly isolated (uncultured) HPCs, indicating that exposure to WT D2 osteoblasts indeed expands functional HSC ex vivo ( Figure 6E , compare white vs. grey striped bars, P<0.05 for myeloid and B cell). In contrast, as predicted from frequency analysis ( Figure   6C ), recipient mice transplanted with HPCs exposed previously to ATM KO D2 osteoblasts (ATM KO D2) showed ~2-fold lower reconstitution of both myeloid and lymphoid lineages as compared to HPCs exposed to WT D2 osteoblasts (55±7% vs. 89±9% for myeloid cells, P<0.05, and 25±2% vs. 55±5.5% for B cells, P<0.05). The engraftment potential of WT HPCs exposed to ATM KO D2 osteoblasts was no greater than that of HPCs exposed to UNT ATM KO osteoblasts, to uncultured HPC, or to HPC cultured alone ( Figure 6E ). Because multi-lineage engraftment potential is a direct measure of HSC activity, this decreased hematopoietic reconstitution in mice transplanted with HPC exposed to ATM KO osteoblasts (Fig. 6E) , combined with the decreased frequency of KTLS HSC in cultures containing ATM KO osteoblasts (Fig. 6C) and the equivalent rate of survival of ATM WT and ATM KO osteoblasts in culture (Fig. 6E) , suggests that ATM plays a key role in the alteration of osteoblast function that normally accompanies Cy/G treatment and that enables D2 mobilized osteoblasts to promote HSC proliferation (Figure 4 ) and expansion of reconstituting activity ( Figure 5 ).
DISCUSSION
Recent studies implicate osteoblasts as an important cellular component of the hematopoietic stem cell niche 4, 8, [54] [55] [56] [57] . These studies demonstrate that in mouse models displaying increased osteoblast cell numbers, there is a concomitant enhancement in the ability of BMderived mixed stroma cultures to support hematopoiesis 3, 7, 57 and an increase in vivo in long-term reconstituting HSC 6 . While these findings suggest that limited availability of osteoblasts may normally limit stem cell expansion, discrimination of the direct vs. indirect effects of osteoblasts on HSC numbers and activity is complicated in these studies by the unavoidable presence of other microenvironmental inputs in the complex cellular milieu of the bone marrow. These issues have spurred significant controversy regarding the particular contribution of the osteoblastic HSC niche, particularly in light of recent suggestions that vascular endothelial cells may provide an "alternative" niche for HSC 1, 14 . Thus, to assay the specific contributions of osteoblasts to the HSC niche, and their role in the regulation of HSC number and function, we directly isolated these putative niche components and directly tested their effect on HSC function. This approach deconstructs the complexity of the marrow environment to ask specifically whether osteoblasts are alone sufficient to regulate HSC activity.
To identify and isolate osteoblasts fresh from the bone, we employed enzymatic digestion coupled with positive and negative selection to specifically purify a population of OPN + CD45 -Ter119 -cells that is highly enriched for osteoblast-specific markers and bone-forming activity.
This efficient and reliable approach to acquire osteolineage cells for study allows the direct analysis of osteoblasts and abrogates the need for extensive cell culture, which can profoundly alter cellular activity. In addition, this strategy allows rapid enumeration of the frequency and number of osteoblasts in vivo, as well as direct assessment of changes in their phenotypic and functional properties under particular in vivo conditions. (It is important to note that, while sorted OPN + cells appear largely homogeneous based on phenotypic ( Fig. 1 and S2 ) and functional ( Fig. 2) analyses, because these cells do not survive at clonal density (data not shown),
we cannot exclude the possibility that additional, rare cell populations co-purify with OPN + cells
and may contribute to their activity.) Nonetheless, this novel prospective isolation approach will be advantageous for a variety of future analyses aimed at understanding the activity of osteolineage cells in different physiological states relevant to both normal and pathological hematopoiesis and bone development.
Making use of this direct osteoblast identification and isolation strategy, we examined the role of osteolineage cells in the clinically relevant induced expansion of HSC that occurs in response to Cy/G treatment. We found that osteoblast numbers and frequency increase significantly in response to Cy/G mobilization. Importantly, expansion of the osteoblastic niche precedes Cy/G-induced HSC expansion, suggesting that osteoblasts may in fact initiate HSC proliferation during stem cell mobilization. Consistent with this notion, osteoblasts isolated from Cy/G-treated mice enhanced the proliferation of naïve (un-mobilized) HSC in short-term coculture assays, as compared to osteoblasts isolated from untreated animals. Moreover, in vivo transplantation of HPC exposed to osteoblasts from Cy/G-treated vs. untreated mice additionally indicated that mobilization-induced changes in the functional interactions of osteoblasts with HSC directly impact the ability of these cells to maintain hematopoietic reconstituting capacity.
Significantly, the molecular mechanism underlying these changes in osteoblast number and function could be traced to the ATM signaling pathway, demonstrating a new role for this kinase in supporting stem cell niche activity. The studies presented here thus provide the first demonstration that changes that occur within the in vivo osteoblastic niche during Cy/G-induced Taken together, our data are consistent with a model (Fig. 7) in which Cy/G mobilization induces functional changes in the interactions of osteoblastic niche cells with HSC, and these changes in turn directly alter HSC activity. Whereas in the absence of osteoblasts, HSCs proliferate in a manner that leads to loss of functional reconstituting activity (likely due to unchecked HSC differentiation 40, 58, 59 ), when exposed to untreated osteoblasts, stem cell proliferation is diminished, and these cells retain reconstituting potential (Fig. 5) . Thus, normal osteoblasts appear to maintain HSC function in part by holding them in a quiescent state 39, 58, 60 .
This restriction of HSC proliferation appears to depend on direct cell-cell contact between the HSC and its niche (Supplementary Fig. 4B ). In contrast, when exposed to HSC mobilizing agents, the osteoblastic niche undergoes dramatic changes. These cells expand significantly, exhibit changes in enzymatic activity consistent with alterations in their differentiation state (Figure 3 & Supplementary Fig. 3) , and elaborate soluble factors that directly promote HSC proliferation (Figure 4 & Supplementary Fig. 4 ) while maintaining their functional reconstituting potential (Fig. 5) . Interestingly, the specific mobilization-induced changes in osteoblast number and function that result from Cy/G treatment (including osteoblast expansion and osteoblast-mediated support of HSC proliferation) are absent in animals lacking ATM (Fig.   6 ).
In summary, these data demonstrate that the osteoblast population present in Cy/Gtreated mice is both phenotypically and functionally distinct from its steady state counterpart, and that changes in the osteoblastic niche, including the ability to support and maintain HSC function, are mediated at least in part by ATM, implicating DNA damage and oxidative stress pathways activated in osteolineage niche cells in the induction of HSC expansion in response to Cy/G. This study thus provides new insight into the cellular and molecular mechanisms underlying the clinically important process of HSC mobilization. In addition, the fact that freshly purified osteoblasts can act autonomously in culture to communicate physiologically appropriate regulatory signals to HSC presents a new and powerful opportunity for direct interrogation of the interactions of stem cells with their niche and for future discovery of novel genes and pathways important in maintaining optimal and appropriate stem cell function. These data will have important future implications for strategies to induce stem cell expansion ex vivo and in the context of bone marrow transplantation.
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For Equivalent frequency of apoptotic (annexin V+,PI-early apoptotic) osteoblasts after 12 hr HPC:OSB co-culture assays. Co-culture assays were performed as described previously and cells were stained for osteoblast specific markers and the cell death and viability markers annexin V (early apoptotic marker) and PI (late apoptotic marker). Representative data is shown for two independent experiments performed. 
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